 We plan to randomize 102 early affected HD patients with a maximum of 120 included patients in France 5UHDRS40 in a randomized, double-blind, controlled study. Patients will receive either resveratrol at 80 mg n51, or placebo n51 for 12 months. Clinical benefit will be respectively evaluated by UHDRS and neuropsychiatric questionnaires; biological tolerance will be evaluated by routine biochemical blood tests and plasma measurements of resveratrol, these three factors will be tested every three months. 